Corporate ActionJun 10, 2026, 04:27 PM
Sensei Biotherapeutics Boosts Authorized Shares to 300M, Approves Equity Plans
AI Summary
Sensei Biotherapeutics' stockholders approved a significant increase in authorized common stock from 12.5 million to 300 million shares. They also approved the 2026 Equity Incentive Plan, reserving 2,671,981 shares initially, and the 2026 Employee Stock Purchase Plan, reserving 267,198 shares initially, both with annual evergreen increases. Additionally, stockholders ratified the appointment of Deloitte & Touche LLP as auditor, re-elected two directors, and approved the issuance of shares for the conversion of Series B Non-Voting Convertible Preferred Stock, which could result in a change of control.
Key Highlights
- Authorized common stock increased from 12.5 million to 300 million shares.
- 2026 Equity Incentive Plan approved with an initial reserve of 2,671,981 shares.
- 2026 ESPP approved with an initial reserve of 267,198 shares.
- Equity plans include annual evergreen increases of 5% and 1% respectively.
- Stockholders approved issuance of shares for Series B Preferred Stock conversion.
- Deloitte & Touche LLP ratified as independent auditor for 2026.
- Bob Holmen and Kristian Humer re-elected as directors until 2029.
Price Impact
More from SNSE